Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N9HB | ISIN: CA25253X2077 | Ticker-Symbol: F2KA
NASDAQ
19.04.24
15:30 Uhr
2,470 US-Dollar
-0,020
-0,80 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DIAMEDICA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DIAMEDICA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DIAMEDICA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoDiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch1
10.04.DiaMedica Therapeutics Inc. - 8-K, Current Report1
25.03.DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript1
21.03.DiaMedica Therapeutics files for $100M mixed securities shelf1
21.03.DiaMedica shares target cut to $8 on study delay1
21.03.DiaMedica shares target cut to $6 by Oppenheimer on trial delay1
20.03.Earnings call: DiaMedica reports on ReMEDy2 trial progress and finances1
19.03.Recap: DiaMedica Therapeutics Q4 Earnings1
19.03.DiaMedica Therapeutics GAAP EPS of -$0.60 in-line1
19.03.DiaMedica Therapeutics Inc. - 10-K, Annual Report1
19.03.DiaMedica Therapeutics Inc. - 8-K, Current Report1
19.03.DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results24MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal...
► Artikel lesen
22.01.DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer-
22.01.DiaMedica Therapeutics names Masuoka as its chief medical officer1
15.11.23DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript-
14.11.23DiaMedica Therapeutics Inc reports results for the quarter ended in September - Earnings Summary1
13.11.23DiaMedica Therapeutics Inc. - 10-Q, Quarterly Report1
13.11.23DiaMedica Therapeutics Inc. - 8-K, Current Report1
13.11.23DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.011
13.11.23DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results128MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1